A randomized, double-blind, placebo-controlled, dose-escalation phase I clinical study evaluating the safety, tolerability and pharmacokinetic profiles of single-dose QR060127 capsule in healthy subjects
Latest Information Update: 13 Jul 2023
At a glance
- Drugs QR-060127 (Primary)
- Indications Pain
- Focus Adverse reactions; Pharmacodynamics
- Sponsors Wuhan Createrna Science and Technology
Most Recent Events
- 12 Jul 2023 New trial record